Meeting Overview - The second meeting of the Supervisory Board of Jinkai (Liaoning) Life Science Co., Ltd. was held on August 22, 2025, with all three supervisors present, ensuring a valid meeting [1][2] Financial Reporting - The Supervisory Board reviewed and confirmed that the company's 2025 semi-annual report and its summary were prepared in accordance with relevant laws and regulations, accurately reflecting the company's financial status and operational results without any false records or omissions [1][2] Fund Management - The company adhered to the regulations regarding the management and use of raised funds, confirming that there were no violations in the storage and management of these funds [2][3] - The proposal to change the method of fund allocation from "loaning to subsidiaries" to "capital increase in subsidiaries" was deemed reasonable and beneficial for improving fund utilization efficiency and protecting shareholder interests [2][3] Cash Management - The use of part of the idle raised funds and self-owned funds for cash management was approved, ensuring it would not affect the investment projects or normal operations of the company [3][4] Capital Supplementation - The proposal to use part of the raised excess funds for permanent working capital supplementation was found to comply with regulations and not conflict with the investment plans [4] Corporate Governance - The revision of the company's articles of association was approved, aimed at optimizing governance and protecting the rights of investors, especially minority shareholders [4][5] Subsidiary Investment - The decision to use self-owned funds to increase capital in Kingchem Life Science LLC for the construction of Kingchem Laboratories Inc. was supported, aligning with the company's strategy to enhance international competitiveness and support global customer needs [5]

Group 1 - The meeting of the fourth supervisory board of Qinhuangdao Tianqin Equipment Manufacturing Co., Ltd. was held on August 21, 2025, with all three supervisors present [1] - The supervisory board reviewed and approved the company's 2025 semi-annual report, confirming that the report accurately reflects the company's actual situation without any false records or significant omissions [1][2] - The supervisory board also confirmed that the management and use of the funds raised in the first half of 2025 comply with relevant regulations and the company's management measures [2]

（二）超募资金使用情况 （一）募集资金投资项目的资金使用情况 报告期内，公司实际投入募投项目的募集资金款项共计人民币 1,840,233.00 元，各募投项目的投入情况及效益情况详见本报告附件 1"募集资金使用情况对 照表"。 证券代码：301338 证券简称：凯格精机 公告编号：2025-025 东莞市凯格精机股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》 《深圳证券交易所创业板股票上市规则》 等相关规定，东莞市凯格精机股份有限公司（以下简称"公司"）编制了 2025 年半年度募集资金存放与使用情况报告，具体情况如下： 一、募集资金基本情况 （一）募集资金金额及到位时间 经中国证券监督管理委员会《关于同意东莞市凯格精机股份有限公司首次公 开发行股票注册的批复》（证监许可[2022]796 号）同意注册，并经深圳证券交 易所同意，公司首次向社会公开发行人民币普通股（A 股）1,900 万股，发行价 格为人民币 46.33 元/股，募集资金 ...

Summary of Key Points Core Viewpoint The company, Huqin Technology Co., Ltd., has completed certain fundraising projects and plans to permanently supplement its working capital with the remaining funds from these projects, following a thorough review by its sponsor, China International Capital Corporation (CICC) [1][9]. Fundraising Basic Information - The company raised a total of RMB 585,195.95 million through its initial public offering, with a net amount of RMB 573,068.36 million after deducting issuance costs, including an oversubscription amount of RMB 23,068.36 million [1][2]. - The funds have been deposited in a dedicated account, and a tripartite/four-party supervision agreement has been signed with the sponsor and the bank [2]. Investment Project Status - The total investment amount for the projects is RMB 669,690.48 million, with RMB 573,068.36 million available for use [3]. - As of May 2025, the Shanghai Emerging Technology R&D Center project and the Wuxi R&D Center Phase II project have reached the predetermined usable status, leading to their conclusion [3][4]. Remaining Funds and Their Use - The remaining funds amount to RMB 34,974.92 million, which will be used to permanently supplement the company's working capital [3][5]. - The company aims to improve the efficiency of fund usage and reduce financial costs through this allocation [6][7]. Reasons for Fund Surplus - The surplus is attributed to effective cost control and resource optimization during project implementation, which did not affect the completion of the fundraising projects [5][6]. - Strategic adjustments in the R&D team and dynamic optimization of construction plans contributed to reduced expenditures [6]. Approval Process and Opinions - The proposal to conclude the fundraising projects and use the surplus funds requires approval from the shareholders' meeting [8]. - The Strategic and Sustainable Development Committee and the Supervisory Board have both expressed support for the proposal, indicating it does not harm the interests of the company or its shareholders [8][9]. Sponsor's Verification Opinion - The sponsor, CICC, has verified that the decision to conclude the projects and use the surplus funds is prudent and aligns with regulatory requirements, ensuring no adverse impact on the company's operations [9].

中国国际金融股份有限公司 关于苏州泽璟生物制药股份有限公司 使用自有资金支付募投项目所需资金并以 募集资金等额置换的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为苏州泽璟生 物制药股份有限公司（以下简称"泽璟制药"或"公司"）的保荐机构和持续督导机构，根 据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规则》《上海证券交易 所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作》等有关法律、行政法规、部门规章及业务规则的要求，对泽璟制药本次使用自 有资金支付募投项目所需资金并以募集资金等额置换的事项进行了认真、审慎核查，具 体情况如下： 一、募集资金基本情况 （一）2020 年首次公开发行 A 股股票募集资金 根据中国证券监督管理委员会 2019 年 12 月 31 日作出的《关于同意苏州泽璟生物 制药股份有限公司首次公开发行股票注册的批复》（证监许可[2019]2998 号），公司获 准向社会公开发行人民币普通股（A 股）60,000,000 股，每股面值人民币 1 元，发行价 格为每股人民币 33.76 元，募集资金总额为人民币 2, ...

Summary of Key Points Core Viewpoint The report provides an overview of the fundraising activities and the management of the raised funds by Shenzhen Ruihua Tai Film Technology Co., Ltd., detailing the amount raised, its usage, and compliance with regulations. Group 1: Fundraising Overview - The total amount raised through the issuance of convertible bonds is RMB 422.58 million, with a net amount of RMB 422.58 million after deducting issuance costs of RMB 7.42 million [1]. - As of June 30, 2025, the company has utilized RMB 426.05 million of the raised funds, including RMB 11.16 million used in the current year [1]. Group 2: Fund Usage and Management - The funds were primarily allocated to the Jiaxing high-performance polyimide film project (RMB 332.90 million) and to supplement working capital and repay bank loans (RMB 93.14 million) [1]. - The company has established a dedicated account for managing the raised funds, ensuring compliance with relevant laws and regulations [1]. Group 3: Financial Performance of Projects - The Jiaxing high-performance polyimide film project has generated revenue of RMB 94.93 million in the first half of 2025, but reported a net loss of RMB 23.84 million, indicating that the project is still in the ramp-up phase with relatively high unit costs [6]. - The project has completed construction and is gradually increasing production efficiency, with four production lines starting operations in September 2023 [5][6].

上海外高桥集团股份有限公司 关于 2025 年半年度募集资金存放与实际使用情况专项报告 为了规范募集资金的管理和使用，提高资金使用效率，保护投资者权益， 上海外高桥集团股份有限公司（以下简称"公司"）根据中国证券监督管理委 员会《上市公司募集资金监管规则》《上海证券交易所上市公司自律监管指引 第1号——规范运作》以及《上海证券交易所上市公司自律监管指南第1号—— 公告格式》的相关规定，将本公司2025年半年度募集资金存放与使用情况专项 报告公告如下： 截至 2025 年 6 月 30 日，公司本期共使用募集资金投入募投项目人民币 （含银行存款利息收入扣除银行手续费后净额）。 截至 2025 年 6 月 30 日，募集资金使用及结余情况如下： 向特定对象发行股票募集资金专户使用情况明细 金额（元） 募集资金净额 2,447,598,658.01 减：募投项目支出 1,890,841,634.44 其中：2025 年募投项目置换支出 958,544,000.00 向特定对象发行股票募集资金专户使用情况明细 金额（元） 减：手续费支出 530.50 加：利息收入 715,571.89 截至 2025 年 6 月 3 ...

湖南天雁机械股份有限公司 募集资金管理制度 第一章 总 则 第一条 为了加强对公司募集资金的使用与管理，提 高募集资金使用效益，保护投资者的合法权益，依据《中华 人民共和国公司法》 、《中华人民共和国证券法》 、《公司监管 指引第 2 号——公司募集资金管理和使用的监管要求》、 《上海证券交易所股票上市规则》 、《上海证券交易所公司自 律监管指引第 1 号——规范运作》等有关法律法规和《湖 南天雁机械股份有限公司章程》 （以下简称《公司章程》）等 规定，并结合公司实际情况，制定本制度。 第二条 本制度所称募集资金系指公司通过发行股 票或者其他具有股权性质的证券，向投资者募集并用于特定 用途的资金监管，但不包括公司为实施股权激励计划募集的 资金监管。 本制度所称超募资金是指实际募集资金净额超过计 划募集资金金额的部分。 第三条 募集资金限定用于公司对外公布的募集资 金投向的项目，未经过公司股东会依法作出决议，不得改变 公司募集资金的用途。募集资金投资项目通过公司的子公司 或公司控制的其他企业实施的，公司应当确保该子公司或控 制的其他企业遵守本募集资金管理制度。 第四条 公司董事会根据有关法律、行政法规、规范性 ...

Group 1 - The report indicates that the company JinKai (Liaoning) Life Science Co., Ltd. has been compliant with information disclosure requirements, with no instances of delayed reviews [1] - The company has established and effectively executed internal regulations to prevent resource occupation by related parties and manage fundraising [1] - The company has conducted monthly checks on its fundraising special accounts, ensuring that project progress aligns with disclosed information [1] Group 2 - The report highlights a slow progress in the investment of fundraising projects, primarily due to changes in international trade policies and market conditions for innovative drugs [3] - There are no reported issues regarding external investments, risk investments, or financial assistance [3] - The company and its shareholders have fulfilled their commitments, with no unfulfilled commitments reported [3]

Core Viewpoint - The board of directors of Dongguan Kaige Precision Machinery Co., Ltd. has approved the 2025 semi-annual report and related documents, confirming their compliance with legal and regulatory requirements, and asserting the accuracy and completeness of the information presented [1][2]. Group 1: Board Meeting Resolutions - The board meeting held on August 21, 2025, was legally convened with all five directors present, and the resolutions passed were deemed valid [1]. - The 2025 semi-annual report and its summary were approved, reflecting the company's actual situation without any false statements or omissions [1][2]. - The special report on the use of raised funds for the first half of 2025 was also approved, confirming compliance with relevant regulations and the absence of any misuse of funds [2]. Group 2: Financial Management Decisions - The board approved the use of up to RMB 400 million of idle raised funds for cash management, allowing investment in high-security and liquid financial products, with a validity period of 12 months [3]. - The board's decision to recognize asset impairment provisions was based on sufficient evidence and compliance with accounting standards, accurately reflecting the company's financial status [3]. - The board approved the use of self-owned assets as collateral for bank credit applications to meet operational funding needs, ensuring no significant financial risk to the company [4]. Group 3: Upcoming Shareholder Meeting - The board has scheduled the first extraordinary general meeting of 2025 for September 9, 2025, to discuss the collateralization proposal, combining on-site and online voting methods [5].